Hybrid In Silico Approach Reveals Novel Inhibitors of Multiple SARS-CoV-2 Variants

The National Center for Advancing Translational Sciences (NCATS) has been actively generating SARS-CoV-2 high-throughput screening data and disseminates it through the OpenData Portal (https://opendata.ncats.nih.gov/covid19/). Here, we provide a hybrid approach that utilizes NCATS screening data from the SARS-CoV-2 cytophatic effect reduction assay to build predictive models, using both machine learning and pharmacophore-based modeling. Optimized models were used to perform two iterative rounds of virtual screening to predict small molecules active against SARS-CoV-2. Experimental testing with live virus provided 100 (~16% of predicted hits) active compounds (Efficacy > 30%, IC50 ≤ 15 μM). Systematic clustering analysis of active compounds revealed three promising chemotypes which have not been previously identified as inhibitors of SARS-CoV-2 infection. Further analysis identified allosteric binders to host receptor angiotensin-converting enzyme 2, which were able to inhibit the entry of pseudoparticles bearing spike protein of wild type SARS-CoV-2 as well as South African B.1.351 and UK B.1.1.7 variants.

[1]  Tudor I. Oprea,et al.  A critical overview of computational approaches employed for COVID-19 drug discovery , 2021, Chemical Society reviews.

[2]  Vishal B. Siramshetty,et al.  Validating ADME QSAR Models Using Marketed Drugs , 2021, SLAS discovery : advancing life sciences R & D.

[3]  B. Villoutreix,et al.  Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises , 2021, Computational and Structural Biotechnology Journal.

[4]  Emily M. Lee,et al.  Biological activity-based modeling identifies antiviral leads against SARS-CoV-2 , 2021, Nature Biotechnology.

[5]  Anton Simeonov,et al.  Large-Scale Modeling of Multispecies Acute Toxicity End Points Using Consensus of Multitask Deep Learning Methods , 2021, J. Chem. Inf. Model..

[6]  Catherine Z. Chen,et al.  Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2 , 2021, Frontiers in Pharmacology.

[7]  Tesia M. Bobrowski,et al.  Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 , 2020, Molecular Therapy.

[8]  Noel Southall,et al.  Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models , 2020, Scientific Reports.

[9]  P. Shinn,et al.  Targeting ACE2–RBD Interaction as a Platform for COVID-19 Therapeutics: Development and Drug-Repurposing Screen of an AlphaLISA Proximity Assay , 2020, ACS pharmacology & translational science.

[10]  An Hong,et al.  Virtual screening of approved clinic drugs with main protease (3CLpro) reveals potential inhibitory effects on SARS-CoV-2 , 2020, Journal of biomolecular structure & dynamics.

[11]  Catherine Z. Chen,et al.  Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening , 2020, ACS pharmacology & translational science.

[12]  Vinicius M. Alves,et al.  QSAR Modeling of SARS‐CoV Mpro Inhibitors Identifies Sufugolix, Cenicriviroc, Proglumetacin, and other Drugs as Candidates for Repurposing against SARS‐CoV‐2 , 2020, Molecular informatics.

[13]  S. Einav,et al.  Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19 , 2020, ACS infectious diseases.

[14]  Catherine Z. Chen,et al.  Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening , 2020, bioRxiv.

[15]  Christoph Nitsche,et al.  The SARS-CoV-2 main protease as drug target , 2020, Bioorganic & Medicinal Chemistry Letters.

[16]  P. Shinn,et al.  Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay , 2020, bioRxiv.

[17]  Sam Michael,et al.  An OpenData portal to share COVID-19 drug repurposing data in real time , 2020, bioRxiv.

[18]  D. Hughes,et al.  Quest for a COVID-19 Cure by Repurposing Small-Molecule Drugs: Mechanism of Action, Clinical Development, Synthesis at Scale, and Outlook for Supply , 2020, Organic process research & development.

[19]  G. Ecker,et al.  Identification of mitochondrial toxicants by combined in silico and in vitro studies – A structure-based view on the adverse outcome pathway , 2020, Computational Toxicology.

[20]  Xin Wang,et al.  Systemic In Silico Screening in Drug Discovery for Coronavirus Disease (COVID-19) with an Online Interactive Web Server , 2020, J. Chem. Inf. Model..

[21]  F. Cheng,et al.  Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 , 2020, Cell Discovery.

[22]  F. Cheng,et al.  Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 , 2020, Cell Discovery.

[23]  T. Langer,et al.  A Combination of Pharmacophore and Docking‐based Virtual Screening to Discover new Tyrosinase Inhibitors , 2020, Molecular informatics.

[24]  A. Elfiky,et al.  Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 , 2020, Life Sciences.

[25]  F. Ban,et al.  Rapid Identification of Potential Inhibitors of SARS‐CoV‐2 Main Protease by Deep Docking of 1.3 Billion Compounds , 2020, Molecular informatics.

[26]  A. Elfiky,et al.  Anti-SARS and anti-HCV drugs repurposing against the Papain-like protease of the newly emerged coronavirus (2019-nCoV) , 2020 .

[27]  Yanjie Wei,et al.  Deep Learning Based Drug Screening for Novel Coronavirus 2019-nCov , 2020, Interdisciplinary Sciences: Computational Life Sciences.

[28]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[29]  M. Alamri,et al.  Pharmacophore and docking-based sequential virtual screening for the identification of novel Sigma 1 receptor ligands , 2019, Bioinformation.

[30]  Hongmao Sun,et al.  Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity. , 2019, Bioorganic & medicinal chemistry.

[31]  Alexander Golbraikh,et al.  Multi-Descriptor Read Across (MuDRA): A Simple and Transparent Approach for Developing Accurate Quantitative Structure-Activity Relationship Models , 2018, J. Chem. Inf. Model..

[32]  Maryam Hamzeh-Mivehroud,et al.  Validation of QSAR Models , 2018 .

[33]  Sankalp Jain,et al.  Comparing the performance of meta-classifiers—a case study on selected imbalanced data sets relevant for prediction of liver toxicity , 2018, Journal of Computer-Aided Molecular Design.

[34]  J B Brown,et al.  Classifiers and their Metrics Quantified , 2018, Molecular informatics.

[35]  Matthias Rarey,et al.  Benchmarking Commercial Conformer Ensemble Generators , 2017, J. Chem. Inf. Model..

[36]  Rua'a A. Al-Aqtash,et al.  Computational modeling of the bat HKU4 coronavirus 3CLpro inhibitors as a tool for the development of antivirals against the emerging Middle East respiratory syndrome (MERS) coronavirus , 2017, Journal of molecular recognition : JMR.

[37]  Sankalp Jain,et al.  Structure based classification for bile salt export pump (BSEP) inhibitors using comparative structural modeling of human BSEP , 2017, Journal of Computer-Aided Molecular Design.

[38]  A. Jadhav,et al.  Highly predictive and interpretable models for PAMPA permeability. , 2017, Bioorganic & medicinal chemistry.

[39]  Alexander Tropsha,et al.  Trust, but Verify II: A Practical Guide to Chemogenomics Data Curation , 2016, J. Chem. Inf. Model..

[40]  Marc C. Nicklaus,et al.  QSAR Modeling and Prediction of Drug-Drug Interactions. , 2016, Molecular pharmaceutics.

[41]  J. Gamieldien,et al.  Potential Broad Spectrum Inhibitors of the Coronavirus 3CLpro: A Virtual Screening and Structure-Based Drug Design Study , 2015, Viruses.

[42]  Alexander Tropsha,et al.  Curation of chemogenomics data. , 2015, Nature chemical biology.

[43]  José Augusto Baranauskas,et al.  How Many Trees in a Random Forest? , 2012, MLDM.

[44]  Ruili Huang,et al.  A Grid Algorithm for High Throughput Fitting of Dose-Response Curve Data , 2010, Current chemical genomics.

[45]  John R. Proudfoot,et al.  Faculty Opinions recommendation of Trust, but verify: on the importance of chemical structure curation in cheminformatics and QSAR modeling research. , 2010 .

[46]  Alexander Tropsha,et al.  Trust, But Verify: On the Importance of Chemical Structure Curation in Cheminformatics and QSAR Modeling Research , 2010, J. Chem. Inf. Model..

[47]  Thorsten Meinl,et al.  KNIME - the Konstanz information miner: version 2.0 and beyond , 2009, SKDD.

[48]  Anatoly G. Artemenko,et al.  Virtual Screening and Molecular Design Based on Hierarchical Qsar Technology , 2009, Recent Advances in QSAR Studies.

[49]  Thierry Langer,et al.  Efficient overlay of small organic molecules using 3D pharmacophores , 2007, J. Comput. Aided Mol. Des..

[50]  Adam Yasgar,et al.  Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[51]  T. Langer,et al.  Pharmacophore definition and 3D searches. , 2004, Drug discovery today. Technologies.

[52]  Tudor I. Oprea,et al.  Virtual Screening in Lead Discovery: A Viewpoint† , 2002, Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry.

[53]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[54]  A. Good,et al.  4.19 – Virtual Screening , 2007 .

[55]  Azriel Rosenfeld,et al.  Machine Learning and Data Mining in Pattern Recognition , 2000, Lecture Notes in Computer Science.

[56]  W. Raub.  From the National Institutes of Health. , 1990, JAMA.